<DOC>
	<DOCNO>NCT01882803</DOCNO>
	<brief_summary>Phase 2 clinical trial evaluate safety efficacy IPI-145 monotherapy subject iNHL ( Follicular Lymphoma , Marginal Zone Lymphoma , Small Lymphocytic Lymphoma ) refractory rituximab either chemotherapy RIT .</brief_summary>
	<brief_title>A Phase 2 Study Duvelisib Subjects With Refractory Indolent Non-Hodgkin Lymphoma ( DYNAMO )</brief_title>
	<detailed_description>This open-label , single arm safety efficacy study IPI-145 administer orally subject diagnose iNHL ( Follicular Lymphoma , Marginal Zone Lymphoma , Small Lymphocytic Lymphoma ) whose disease refractory rituximab either chemotherapy RIT . Approximately 120 subject receive 25 mg IPI-145 BID course 28-day treatment cycle 13 cycle . After complete 13 treatment cycle IPI-145 , subject may continue receive additional cycle IPI-145 disease progression unacceptable toxicity . However , receive additional cycle IPI-145 beyond 13 cycle , subject must evidence response ( CR PR ) accord IWG criteria1 end Cycle 13 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Subjects diagnose indolent NHL progress . Subjects must exhibit lack CR PR progression within 6 month last dose chemotherapy induction regimen RIT . Subjects must rituximabrefractory disease , define lack CR PR PD within 6 month last dose . Measurable disease lymph node tumor mass â‰¥1.5 cm least one dimension CT , PET/CT MRI . Adequate renal hepatic function . Candidate potentially curative therapy opinion investigator . Previous treatment PI3K inhibitor BTK inhibitor . Prior history allogeneic hematopoietic stem cell transplant ( HSCT ) . Prior chemotherapy , cancer immunosuppressive therapy , investigational agent within 4 week first dose study drug . Grade 3B FL and/or clinical evidence transformation aggressive subtype lymphoma . Symptomatic central nervous system ( CNS ) NHL . Ongoing systemic bacterial , fungal , viral infection time initiation study treatment . Prior , current , chronic hepatitis B hepatitis C infection , positive result hepatitis C virus antibody ( HCV Ab ) hepatitis B surface antigen ( HBsAg ) hepatitis B core antibody ( HBcAb ) History stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication mechanical control within last 6 month prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>PI3K Inhibitor</keyword>
</DOC>